Compare Stocks → Biden replacement revealed? (From Paradigm Press) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CNSPNASDAQ:CWBRNASDAQ:CYCCNASDAQ:NTBL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNSPCNS Pharmaceuticals$0.22+4.8%$0.30$0.19▼$2.98$2.32M2.67349,355 shs72,919 shsCWBRCohBar$0.86$0.83$0.51▼$6.90$2.50M1.54843 shs36 shsCYCCCyclacel Pharmaceuticals$2.65+25.0%$2.21$1.30▼$13.20$3.50M0.54650,706 shs17.48 million shsNTBLNotable Labs$0.91-1.1%$1.40$0.83▼$11.20$2.03M0.77164,218 shs100,950 shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNSPCNS Pharmaceuticals-2.33%0.00%-41.99%-15.32%-86.96%CWBRCohBar0.00%-4.48%-2.28%-0.98%-51.41%CYCCCyclacel Pharmaceuticals+55.88%+18.44%+0.48%-5.36%-76.05%NTBLNotable Labs-5.28%-6.12%-48.02%-25.81%+91,999,900.00%The “Next Bitcoin”? 10 CENT Crypto Set to Explode (Ad)The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNSPCNS PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACWBRCohBarN/AN/AN/AN/AN/AN/AN/AN/ACYCCCyclacel Pharmaceuticals1.6886 of 5 stars3.33.00.00.02.80.00.6NTBLNotable Labs3.2049 of 5 stars3.55.00.00.03.11.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNSPCNS PharmaceuticalsN/AN/AN/AN/ACWBRCohBarN/AN/AN/AN/ACYCCCyclacel Pharmaceuticals2.50Moderate Buy$21.00692.45% UpsideNTBLNotable Labs3.00Buy$8.00775.23% UpsideCurrent Analyst RatingsLatest CWBR, CNSP, CYCC, and NTBL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/15/2024NTBLNotable LabsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$9.004/15/2024NTBLNotable LabsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$9.00 ➝ $7.00(Data available from 5/1/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNSPCNS PharmaceuticalsN/AN/AN/AN/A($0.71) per shareN/ACWBRCohBarN/AN/AN/AN/A$5.27 per shareN/ACYCCCyclacel Pharmaceuticals$420K8.33N/AN/A$0.57 per share4.65NTBLNotable Labs$310K6.55N/AN/A$6.81 per share0.13Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNSPCNS Pharmaceuticals-$18.85M-$5.66N/A∞N/AN/A-603.40%-421.35%5/20/2024 (Estimated)CWBRCohBar-$12.18M-$4.36N/A∞N/AN/AN/AN/A5/13/2024 (Estimated)CYCCCyclacel Pharmaceuticals-$22.56M-$27.22N/AN/AN/AN/A-448.19%-151.29%5/9/2024 (Estimated)NTBLNotable Labs-$11.26M-$3.63N/A∞N/AN/A-62.07%-48.32%5/20/2024 (Estimated)Latest CWBR, CNSP, CYCC, and NTBL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q4 2023CNSPCNS PharmaceuticalsN/A-$0.95-$0.95-$0.95N/AN/A3/19/2024Q4 2023CYCCCyclacel Pharmaceuticals-$6.35-$6.23+$0.12-$6.23N/A$0.03 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNSPCNS PharmaceuticalsN/AN/AN/AN/AN/ACWBRCohBarN/AN/AN/AN/AN/ACYCCCyclacel PharmaceuticalsN/AN/AN/AN/AN/ANTBLNotable LabsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNSPCNS PharmaceuticalsN/A0.260.26CWBRCohBarN/AN/AN/ACYCCCyclacel PharmaceuticalsN/A0.910.91NTBLNotable Labs0.025.655.65OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNSPCNS Pharmaceuticals14.02%CWBRCohBar2.47%CYCCCyclacel Pharmaceuticals23.58%NTBLNotable Labs70.48%Insider OwnershipCompanyInsider OwnershipCNSPCNS Pharmaceuticals9.20%CWBRCohBar6.51%CYCCCyclacel Pharmaceuticals8.47%NTBLNotable Labs1.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCNSPCNS Pharmaceuticals310.64 million9.66 millionNot OptionableCWBRCohBar92.91 million2.72 millionNot OptionableCYCCCyclacel Pharmaceuticals2,0181.32 million1.21 millionOptionableNTBLNotable Labs132.22 million2.19 millionNo DataCWBR, CNSP, CYCC, and NTBL HeadlinesSourceHeadlineNTBL Notable Labs, Ltd.seekingalpha.com - April 30 at 10:51 PMNotable Labs (NTBL) Upgraded to Buy: What Does It Mean for the Stock?zacks.com - April 19 at 1:01 PMCisco To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Mondaymsn.com - April 16 at 2:41 PMBuy Rating for Notable Labs: Financial Stability and Strategic Advances in AML Clinical Trialsmarkets.businessinsider.com - April 15 at 7:32 AMNTBL Stock Earnings: Notable Labs Misses EPS for Q4 2023investorplace.com - April 12 at 3:05 PMNotable Labs Reports 2023 Financial Results and Provides a Business Updateglobenewswire.com - April 12 at 8:00 AMNotable Labs advances cancer treatment with cryopreserved samplesinvesting.com - April 10 at 4:01 PMNotable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024globenewswire.com - April 9 at 5:15 PMNotable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platformglobenewswire.com - April 8 at 12:00 PMNotable Labs to Present Two Posters at AACR 2024 on PPMP Platformglobenewswire.com - March 5 at 4:35 PMNotable Labs to Present Two Posters at AACR 2024 on PPMP Platformglobenewswire.com - March 5 at 4:35 AMNotable Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollmentfinance.yahoo.com - February 22 at 8:15 AMNotable Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollmentglobenewswire.com - February 22 at 8:00 AMMaintained Buy Rating on Notable Labs with Adjusted Price Target Amid Drug Setback and PPMP Platform Potentialmarkets.businessinsider.com - December 21 at 12:06 AMNotable Reports Predictive Precision Medicine Platform (PPMP) Accurately Predicted Fosciclopirox Trial Outcomefinance.yahoo.com - December 18 at 9:01 AMNotable Reports Predictive Precision Medicine Platform (PPMP) Accurately Predicted Fosciclopirox Trial Outcomefinance.yahoo.com - December 18 at 9:01 AMNotable Labs Ltd (NTBL)investing.com - December 14 at 2:02 PMNotable Labs Donates $60,000 to MDS Foundation to Accelerate Progress for Patients with Myelodysplastic Syndromesfinance.yahoo.com - December 13 at 2:57 PMNotable Labs Funds Myelodysplastic Syndromes Foundation with $60,000 Grantfinance.yahoo.com - December 11 at 2:02 PMNotable Labs to Participate in JMP Securities Hematology and Oncology Summitfinance.yahoo.com - December 4 at 7:48 PMNotable Labs Ltd NTBLmorningstar.com - November 29 at 8:53 PMKeay Nakae’s Buy Rating on Notable Labs: Predictive Precision Medicine Platform and Financial Stability as Key Factorsmarkets.businessinsider.com - November 21 at 9:59 AMNotable Labs: Q3 Earnings Snapshotwashingtonpost.com - November 16 at 8:31 AMNotable Labs Announces Filing of Form 10-Q for Third Quarter 2023finance.yahoo.com - November 16 at 8:31 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCNS PharmaceuticalsNASDAQ:CNSPCNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.CohBarNASDAQ:CWBRCohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.Cyclacel PharmaceuticalsNASDAQ:CYCCCyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.Notable LabsNASDAQ:NTBLNotable Labs, Ltd., a clinical-stage platform therapeutics company, engages in developing predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient is likely to respond to that specific therapeutic. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and thus fast-track clinical development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor for acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes indications; and Fosciclopirox, a pro-drug of ciclopirox for AML. Notable Labs, Ltd. is headquartered in Foster City, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
